In the past several years, the concept of tissue-selective nuclear receptor ligands has emerged. This concept has come to fruition with estrogens, with the successful marketing of drugs such as raloxifene. The discovery of raloxifene and other selective estrogen receptor modulators (SERMs) has raised the possibility of generating selective compounds for other pathways, including androgens (that is, selective androgen receptor modulators, or SARMs).
References
1.
CarminaE., and LoboR. A. (2002). A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic womenClin Endocrinol (Oxf)57, 231–4.
2.
DaltonJ.T., MillerD.D., YinD., and HeY. (2002). Preparation of 3-phenoxypropionic acid 4-nitro-3-trifluoromethylbenzamides as selective androgen receptor modulators.
3.
Diamanti-KandarakisE. (1999). Current aspects of antiandrogen therapy in womenCurr Pharm Des5, 707–23.
4.
FlynnV., and HellstromW. J. (2001). Androgen deficiency in the aging male: pathophysiology, diagnosis, and treatment alternativesCurr Urol Rep2, 473–9.
5.
HamannL. G., ManiN. S., DavisR. L., WangX. N., MarschkeK. B., and JonesT. K. (1999). Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071)J Med Chem42, 210–2.
6.
HeinleinC. A., and ChangC. (2002). Androgen receptor (AR) coregulators: an overviewEndocr Rev23, 175–200.
7.
MatiasP. M., DonnerP., CoelhoR., ThomazM., PeixotoC., MacedoS., OttoN., JoschkoS., ScholzP., WeggA., BaslerS., SchaferM., EgnerU., and CarrondoM. A. (2000). Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutationsJ Biol Chem275, 26164–71.
8.
McLeodD. G., and IversenP. (2000). Gynecomastia in patients with prostate cancer: a review of treatment optionsUrology56, 713–20.
9.
MiyachiH., AzumaA., KitamotoT., HayashiK., KatoS., KogaM., SatoB., and HashimotoY. (1997) Potent novel nonsteroidal androgen antagonists with a phthalimide skeleton. Bioorg. Med. Chem. Lett.7, 1483–1488.
10.
MooradianA. D., MorleyJ. E., and KorenmanS. G. (1987). Biological actions of androgensEndocr Rev8, 1–28.
11.
MuderrisI.I., BayramF., OzcelikB., and GuvenM. (2002). New alternative treatment in hirsutism: bicalutamide 25 mg/dayGynecol Endocrinol16, 63–6.
12.
PanH. J., WildingG., UnoH., InuiS., GoldsmithL., MessingE., and ChangC. (1998). Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaquesEndocrine9, 39–43.
13.
SackJ. S., KishK. F., WangC., AttarR. M., KieferS. E., AnY., WuG. Y., SchefflerJ. E., SalvatiM. E., KrystekS. R.Jr., WeinmannR., and EinspahrH. M. (2001). Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosteroneProc Natl Acad Sci U S A98, 4904–9.
14.
SalvatiM. E., GottardisM.M., KrystekS.R.Jr., AttarR.M., and SackJ.S. (2002). Synthesis of selective androgen receptor modulators and methods for their identification, design and use
15.
SeeW. A., WirthM. P., McLeodD. G., IversenP., KlimbergI., GleasonD., ChodakG., MontieJ., TyrrellC., WallaceD. M., DelaereK. P., VaageS., TammelaT. L., LukkarinenO., PerssonB. E., CarrollK., and KolvenbagG. J. (2002). Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer programJ Urol168, 429–35.
16.
SintovA., SerafimovichS., and GilharA. (2000). New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto miceInt J Pharm194, 125–34.
17.
StoneN. N., and ClejanS. J. (1991). Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasiaJ Androl12, 376–80.
18.
VenturoliS., MarescalchiO., ColomboF. M., MacrelliS., RavaioliB., BagnoliA., ParadisiR., and FlamigniC. (1999). A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutismJ Clin Endocrinol Metab84, 1304–10.
19.
VenturoliS., ParadisiR., BagnoliA., ColomboF. M., RavaioliB., VianelloF., ManciniF., GualerziB., PorcuE., and SeracchioliR. (2001). Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutismHorm Res56, 25–31.
